Abstract
Cytochrome P450 enzymes are a superfamily of enzymes involved in the metabolism of endogenous compounds as well as xenobiotics. Due to the large number of reactions catalyzed by these enzymes and their importance in drug metabolism and carcinogenesis, they have been the focus of many studies over the years. Based on the knowledge that flavones are natural substrates of certain P450 enzymes (such as P450 1A2) involved in carcinogenesis, we have synthesized and studied a number of flavonoids as potential inhibitors of these enzymes. These compounds are structurally very similar to the natural flavone substrates of these enzymes but have methoxy substituents at various positions. Here we are reporting the synthesis, structural analysis, X-ray crystal structures, and preliminary inhibition studies of four methoxyflavones from this series. Crystallographic data: 2′-methoxyflavone, P-1, a = 7.2994(8) Å, b = 8.3322(7) Å, c = 10.8240(10) Å, α = 97.905(8)°, β = 92.779(10)°, γ = 111.105(8)°, V = 604.9(1) Å3; 3′-methoxyflavone, P21/n, a = 15.1313(16) Å, b = 3.9699(4) Å, c = 19.9454(16) Å, β = 91.673(8)°, V = 1197.6(2) Å3; 4′-methoxyflavone, P21/n, a = 16.451(12) Å, b = 3.881(1) Å, c = 19.529(16) Å, β = 106.65(1)°, V = 1195.1(4) Å3; 3′,4′-dimethoxyflavone, C2/c, a = 30.819(5) Å, b = 4.0857(7) Å, c = 26.100(3) Å, β = 124.21(1)°, V = 2717.6(7) Å3.
Index Abstract
Methoxyflavone Inhibitors of Cytochrome P450
Michael McKendall, Tasha Smith, Kien Anh, Jamie Ellis, Terri McGee, Maryam Foroozesh, Naijue Zhu and Cheryl L. Klein Stevens*
This paper is a report of the synthesis, structural analysis, X-ray crystal structures, and preliminary inhibition studies of 2′-methoxyflavone, 3′-methoxyflavone, 4′-methoxyflavone, and 3′,4′-dimethoxyflavone.
Similar content being viewed by others
Notes
Conventional reliability indices: R = ∑||F o| − |F c||/∑|F o|, and R w = (∑(|F o| − |F c|)2/∑w|F o|2)½, where F o and F c are observed and calculated structure factors, w = 1/σ(F)2, and where σ(F) is the estimated standard deviation in F o.
References
Guengerich FP (2004) In: Oritz de Montellano PR (ed) Cytochrome P450 structure, mechanism, and biochemistry. Kluwer Academic/Plenum Publisher, New York, pp 377–463
Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA, Deisenhofer J (1995) Curr Biol 3:41
Capdevila JH, Zeldin D, Makita K, Karara A, Falck JR (2004) In: Ortiz de Montellano PR (ed) Cytochrome P450 structure, mechanism, and biochemistry. Kluwer Academic/Plenum Publisher, New York, pp 531–545
Raner GM, Vas ADN, Coon MJ (1996) Mol Pharmacol 49:515
Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE (2000) Mol Cell 5:121
Schenkman JB, Greim H (eds) (1993) Cytochrome P450 handbook of experimental pharmacology, vol 105. Springer-Verlag, Berlin, pp 1–739
Guengerich FP, Kim D-H, Iwasaki M (1991) Chem Res Toxicol 4:168
Zhang JY, Wang Y, Prakash C (2006) Curr Drug Metab 7(8):939
Estabrook RW (1996) FASEB J 10:202
Masters BSS (1996) FASEB J 10:205
Graham-Lorence S, Peterson JA (1996) FASEB J 10:206
Whitlock JP Jr, Okino ST, Dong L, Ko HP, Clarke-Katenberg R, Ma Q, Li H (1996) FASEB J 10:809
Gonzales FJ, Lee YH (1996) FASEB J 10:112
Johnson EF, Palmer CNA, Griffin KJ, Hsu MH (1996) FASEB J 10:1241
Prough RA, Linder MW, Pinaire JA, Xiao GA, Falkner KC (1996) FASEB J 10:1369
Park KY, Jung GO, Lee KT, Choi J, Choi MY, Kim GT, Jung HJ, Park HJ (2004) J Ethnopharmacol 90(1):73
Uhl M, Ecker S, Kassie F, Lhoste E, Chakraborty A, Mohn G, Knasmueller S (2003) Arch Toxicol 77(8):477
Alworth WL, Viaje A, Sandoval A, Warren BS, Slage TJ (1991) Carcinogenesis 12:1209
Alworth WL, Young-Sciame Y, Hecht SS (1993) Carcinogenesis 14:1711
Christou M, Moore CJ, Gould MN, Jefcoate CR (1987) Carcinogenesis 8:73
Ares JJ, Outt PE, Kakodkar SV, Busse RC, Geiger JG (1993) J Org Chem 58:7903
Mackay S, Gilmore CJ, Edwards C, Stewart N, Shankland K (1999) MaXus computer program for the solution and refinement of crystal structures. Bruker Nonius, The Netherlands; MacScience: Japan and The University of Glasgow
Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT (1994) Biochem Pharmacol 48:923
Buters JT, Schiller CD, Chou RC (1993) Biochem Pharmacol 46:1577
Deluca JG, Dysaft GR, Rasnick D, Bradley MO (1989) Biochem Pharmacol 37:1731
Hopkins NE, Foroozesh MK, Alworth WL (1992) Biochem Pharmacol 44:787
Bhattacharya KK, Brake PB, Elton SE, Otto SA, Jefcoate CR (1995) J Biol Chem 270:11595
Nuwaysir EF, Dragan YP, Jefcoate CR, Jordan VC, Pitot HC (1995) Cancer Res 55:1780
Robertson DW, Katzenellenbogen JA, Long DJ, Rorke EA, Katzenellenbogen BS (1982) J Steroid Biochem 16:1
Styles JA, Davies A, Lim CK, de Matties F, Stanley LA, White INH, Yuan ZX, Smith LL (1994) Carcinogenesis 15:5
Pathak D, Bodell WJ (1994) Carcinogenesis 15:529–532
SYBYL Molecular Modeling Software, Version 7.3 (2007) Tripos Associates Inc.; St. Louis, Missouri 63144
Acknowledgements
Support of this research from the NIH/MBRS-SCORE Program (S06 GM08008) is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McKendall, M., Smith, T., Anh, K. et al. Methoxyflavone Inhibitors of Cytochrome P450. J Chem Crystallogr 38, 231–237 (2008). https://doi.org/10.1007/s10870-007-9310-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10870-007-9310-x